Serum Concentration of Transforming Growth Factor (TGF)-Beta 1 Does Not Predict Advanced Liver Fibrosis in Children with Chronic Hepatitis B

Hepato-Gastroenterology

Volumn 51, Issue 55, 2004, Pages 229-233

  Lebensztejn, Dariusz Marek ^a   Sobaniec Lotowska, Maria ^a   Kaczmarski, Maciej ^a   Werpachowska, Irena ^a   Sienkiewicz, Jerzy ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Children; Chronic hepatitis B; Interferon alpha; Liver fibrosis; Transforming growth factor beta 1

Indexed keywords

ALPHA2A INTERFERON; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ARTICLE; CHILD; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; ROC CURVE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 10744219791     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247-2250.
2. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Eng J Med. 2001; 344:495-500.
3. Piccinino F, Sagnelli E, Pasquale G, Guisti G: Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2:165-173.
4. Maharaj B, Maharaj RJ, Leary WP, et al: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1:523-525.
5. Oberti F, Valsesia E, Pilette C, et al: Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113:1609-1616.
6. Plebani M, Burlina A: Biochemical markers of hepatic fibrosis. Clin Biochem 1991; 24:219-239.
7. Schuppan D, Stolzel U, Oesterling C, Somasundaram R: Serum assays for liver fibrosis. J Hepatol 1995; 22(Suppl 2):82-88.
8. Batts KP, Ludwig J: Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409-1417.
9. Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
10. Roberts AB, Sporn MB: The transforming growth factor-betas. In: Roberts AB, Sporn MB (Eds.). Peptide Growth Factors and Their Receptors. I. New York: Springer-Verlag, 1990; pp. 419-472.
11. Junker U, Haufe CC, Nuske K, et al: Elevated plasma TGF-beta1 in renal diseases: cause or consequence? Cytokine 2000; 12:1084-1091.
12. Gleizes PE, Munger JS, Nunes I, et al: TGF-beta latency: biological significance and mechanisms of activation. Stem Cells 1997; 15:190-197.
13. Roulot D, Durand H, Coste T, et al: Quantitative analysis of transforming growth factor betal messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology 1995; 21:298-304.
14. Friedman SL: The cellular basis of hepatic fibrosis. N Eng J Med 1993; 328:1828-1835.
15. Casini A, Pinzani M, Milani S, et al: Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology 1993; 105:245-253.
16. Grungreiff K, Reinhold D, Ansorge S: Serum concentration of sIL-2R, IL-6, TGF-beta1, neopterin and zinc in chronic hepatitis C patients treated with interferon-alpha. Cytokine 1999; 11:1076-1080.
17. Flisiak R, Prokopowicz D: Transforming growth factor-beta1 as surrogate marker of hepatic dysfunction in chronic liver diseases. Clin Chem Lab Med 2000; 38:1129-1131.
18. Tsushima H, Kawata S, Tamura S, et al: Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J Hepatol 1999; 30:1-7.
19. Castilla A, Prieto J, Fausto N: Transforming growth factors betal and alpha in chronic liver disease. Effects of interferon alfa therapy. N Eng J Med. 1991; 324:933-94 0.
20. Nelson DR, Gonzales-Peralta RP, et al: Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat 1997; 4:29-35.
21. Flisiak R, Pytel-Korolczuk B, Prokopowicz D: Circulating transforming growth factor beta1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12:677-681.
22. Lamireau T, Le Bail B, Boussarie L, et al: Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 (TGF beta1) in biliary atresia and paucity of intrahepatic bile ducts during infancy. J Hepatol 1999; 31:248-255.
23. Imbert-Bismut F, Ratziu V, Pieroni L, et al: Biochemical markers of liver fibrosis in patients with chronic hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
24. Ueki T, Kaneda Y, Tsutsui H, et al: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5:226-230.
25. Luo R, Yang S, Xie J, et al: Diagnostic value of five serum markers of liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2001; 9:148-150.
26. Ruiz-Moreno M, Rua MJ, Molina J, et al: Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991; 13:1035-1039.
27. Ozer E, Ozer E, Helvaci M, Yaprak I: Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy. Liver 1999; 19:369-374.
28. Fujisawa T, Komatsu H, Inui A, et al: Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J Pediatr Gastroenterol Nutr 2000; 30:201-206.
29. Gregorio GV, Jara P, Hierro L, et al: Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23:700-707.
30. Ruiz-Moreno M, Otero M, Millan A, et al: Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology 1999; 29:572-575.
31. Shindo M, Arai K, Okuno T: The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. J Hepatol 1997; 26:492-497.
32. Vida S: A computer program for non-parametric receiver operating characteristic analysis. Comput Methods Programs Biomed 1993; 40:95-101.